Profile data is unavailable for this security.
About the company
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
- Revenue in EUR (TTM)2.55bn
- Net income in EUR404.39m
- Incorporated--
- Employees4.58k
- LocationRecordati Industria Chimica e Farmaceutica SpAVia Matteo Civitali, 1MILANO 20148ItalyITA
- Phone+39 2487871
- Fax+39 240073747
- Websitehttps://recordati.com/
More ▼
Mergers & acquisitions
| Acquired company | REC:MIL since announced | Transaction value |
|---|---|---|
| Impact Biomedicines Inc-Japan Inrebic Business | -2.60% | -- |
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences Ltd | 2.29bn | 459.58m | 8.35bn | 27.92k | 18.16 | 3.53 | 14.94 | 3.65 | 48.90 | 48.89 | 243.42 | 251.51 | 0.6253 | 1.60 | 5.09 | 8,773,830.00 | 12.70 | 10.92 | 17.02 | 16.35 | 72.40 | 63.12 | 20.30 | 16.73 | 1.44 | -- | 0.2554 | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Jazz Pharmaceuticals PLC | 3.52bn | -311.83m | 8.51bn | 2.80k | -- | 2.54 | 31.65 | 2.42 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| WuXi XDC Cayman Inc | 620.64m | 161.88m | 8.59bn | 2.27k | 54.80 | 9.05 | 48.31 | 13.84 | 1.15 | 1.15 | 4.41 | 6.97 | 0.5687 | 21.58 | 3.31 | 2,807,727.00 | 14.83 | -- | 19.71 | -- | 33.01 | -- | 26.08 | -- | 2.14 | -- | 0.1225 | -- | 90.80 | -- | 277.24 | -- | -- | -- |
| Lupin Ltd | 2.31bn | 403.96m | 9.28bn | 19.98k | 23.02 | 5.06 | 17.65 | 4.01 | 94.43 | 94.43 | 540.38 | 429.82 | 0.8393 | 1.25 | 4.34 | 12,388,350.00 | 14.74 | 4.53 | 21.74 | 7.16 | 71.70 | 59.70 | 17.57 | 5.95 | 1.32 | 110.56 | 0.2396 | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Biomarin Pharmaceutical Inc | 2.62bn | 440.40m | 9.45bn | 3.04k | 21.79 | 1.84 | 18.52 | 3.61 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Avidity Biosciences Inc | 17.66m | -465.25m | 9.55bn | 391.00 | -- | 5.67 | -- | 540.57 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Dr Reddy's Laboratories Ltd | 3.24bn | 520.13m | 9.65bn | 26.94k | 18.58 | -- | 13.82 | 2.98 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Recordati Industria Chmc Frmctc SpA | 2.55bn | 404.39m | 9.87bn | 4.58k | 24.04 | 5.01 | 16.11 | 3.86 | 1.96 | 1.96 | 12.40 | 9.42 | 0.5377 | 1.81 | 4.87 | 557,416.80 | 8.51 | 10.50 | 10.71 | 13.46 | 67.66 | 69.89 | 15.83 | 19.98 | 1.16 | 8.30 | 0.5651 | 36.98 | 12.45 | 9.58 | 7.01 | 2.46 | 13.94 | 4.90 |
| Financiere de Tubize SA | 0.00 | 92.74m | 10.02bn | -- | 108.00 | 5.17 | 107.99 | -- | 2.08 | 2.08 | 0.00 | 43.49 | 0.00 | -- | -- | -- | 4.81 | 5.68 | 4.85 | 5.89 | -- | -- | -- | 230.34 | -- | -- | 0.00 | 30.18 | -- | -- | 2.22 | -20.50 | -- | 10.90 |
| Cipla Ltd | 2.65bn | 424.67m | 10.04bn | 30.31k | 23.64 | -- | 19.30 | 3.79 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Orion Oyj | 1.63bn | 313.30m | 10.41bn | 4.03k | 33.13 | 10.20 | 28.67 | 6.39 | 2.23 | 2.23 | 11.59 | 7.24 | 0.9707 | 1.55 | 6.55 | 419,768.00 | 18.66 | 20.14 | 26.08 | 24.67 | 59.66 | 59.72 | 19.22 | 21.16 | 1.19 | 101.62 | 0.234 | 84.25 | 29.65 | 7.97 | 52.17 | 10.48 | 19.14 | 1.80 |
| Elanco Animal Health Inc | 3.89bn | 30.46m | 10.60bn | 9.00k | 351.86 | 1.86 | 17.74 | 2.73 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| BridgeBio Pharma Inc | 299.38m | -674.55m | 11.10bn | 725.00 | -- | -- | -- | 37.07 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
Data as of Feb 06 2026. Currency figures normalised to Recordati Industria Chimica e Farmaceutica SpA's reporting currency: Euro EUR
16.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management Ltd.as of 22 Oct 2025 | 8.61m | 4.12% |
| Fidelity Management & Research Co. LLCas of 31 Oct 2024 | 7.38m | 3.53% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 4.27m | 2.04% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 2.31m | 1.10% |
| Mawer Investment Management Ltd.as of 30 Sep 2025 | 2.19m | 1.05% |
| Norges Bank Investment Managementas of 29 Apr 2025 | 2.02m | 0.97% |
| Fundsmith LLPas of 29 Apr 2025 | 1.81m | 0.86% |
| Fidelity Investments Canada ULCas of 30 Nov 2025 | 1.75m | 0.84% |
| Geode Capital Management LLCas of 29 Jan 2026 | 1.74m | 0.83% |
| Financi�re de l'�chiquier SAas of 29 Apr 2025 | 1.61m | 0.77% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
